Authors: | Zeidan, A. M.; Lee, J. W.; Prebet, T.; Greenberg, P.; Sun, Z.; Juckett, M.; Smith, M. R.; Paietta, E.; Gabrilove, J.; Erba, H. P.; Tallman, M. S.; Gore, S. D. |
Article Title: | Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes |
Abstract: | Summary: The revised International Prognostic Scoring System (IPSS-R) was developed in a cohort of untreated myelodysplastic syndromes (MDS) patients. A French Prognostic Scoring System (FPSS) was recently reported to identify differential survival among azacitidine-treated patients with high-risk MDS. We applied the FPSS and IPSS-R to 150 patients previously randomized to azacitidine monotherapy or a combination of azacitidine with entinostat (a histone deacetylase inhibitor). Neither score predicted response but both discriminated patients with different overall survival (OS; median OS, FPSS: 9·7, 14·7, and 25·3 months, P = 0·018; IPSS-R: 12·5, 11·3, 20·8, and 36 months, P = 0·005). Statistical analysis suggested no improvement in OS prediction for the FPSS over the IPSS-R in azacitidine-treated patients. © 2014 John Wiley & Sons Ltd. |
Keywords: | prognostic models; azacitidine; myelodysplastic syndromes; french prognostic scoring system; revised international prognostic scoring system |
Journal Title: | British Journal of Haematology |
Volume: | 166 |
Issue: | 3 |
ISSN: | 0007-1048 |
Publisher: | John Wiley & Sons |
Date Published: | 2014-08-01 |
Start Page: | 352 |
End Page: | 359 |
Language: | English |
DOI: | 10.1111/bjh.12884 |
PROVIDER: | scopus |
PUBMED: | 24712482 |
PMCID: | PMC4299460 |
DOI/URL: | |
Notes: | Export Date: 1 August 2014 -- CODEN: BJHEA -- Source: Scopus |